- ►wanfang.gov.tw [DOC] RE Amori, J Lau, AG Pittas - Jama, 2007 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 248 - Related articles - BL Direct - All 8 versions
DJ Drucker, JB Buse, K Taylor, DM Kendall, M … - The Lancet, 2008 - Elsevier A 30-week, randomised, non-inferiority study compared a long-acting release
formulation of exenatide 2 mg administered once weekly to 10 μg exenatide
administered twice a day, in 295 patients with type 2 diabetes (haemoglobin ... Cited by 37 - Related articles - All 4 versions
A Barnett - Expert Opin. Pharmacother., 2007 - informahealthcare.com Exenatide is the first in a new class of compounds, which possess similar
activity to the naturally-occurring hormone glucagon-like peptide-1 (GLP-1). It
mirrors many of the effects of GLP-1, improving glycaemic control through a ... Cited by 27 - Related articles - BL Direct - All 8 versions
S Madsbad, T Krarup, CF Deacon, JJ Holst - Current Opinion in Clinical Nutrition & Metabolic Care, 2008 - journals.lww.com Recent findings: The injectable glucagon-like peptide-1 receptor agonists
exenatide significantly improves glycaemic control, with average reductions in
haemoglobin A1c of about 1.0%, fasting plasma glucose of about 1.4 mmol/l, ... Cited by 25 - Related articles - All 2 versions
- ►endojournals.org CW Chia, JM Egan - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc Evidence Synthesis: Exenatide and liraglutide are injection based. Three-year
follow-up data on exenatide showed a sustained weight loss and glycosylated
hemoglobin (HbA 1c ) reduction of 1%. Nausea and vomiting are common. ... Cited by 24 - Related articles - All 5 versions
C Pan, W Yang, JP Barona, Y Wang, M Niggli … - Diabetic Medicine, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 16 - Related articles - BL Direct - All 4 versions
AD Mazza, JE Morley - Journal of the American Medical Directors Association, 2007 - Elsevier Therapeutic focus in the long-term care population shifts toward medical
management, ranging from insulin to alternate interventions, such as metformin,
sulfonylureas, thiazelionediones (TZDs), α-glucosidase inhibitors, and, ... Cited by 15 - Related articles - All 15 versions
- ►endojournals.org M Salehi, BA Aulinger, DA D'Alessio - Endocrine Reviews, 2008 - Endocrine Soc THE LAST TWO DECADES have seen a major shift in the consensus on the
pathogenesis of type 2 diabetes mellitus (T2DM). Although it is clear that
resistance of peripheral tissues to insulin is an abnormality common to ... Cited by 15 - Related articles - BL Direct - All 4 versions
- ►endojournals.org SC Woods, DA D'Alessio - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc Evidence Synthesis: During meals, signals such as cholecystokinin arise
primarily from the GI tract to cause satiation and meal termination; signals
secreted in proportion to body fat such as insulin and leptin interact with ... Cited by 16 - Related articles - All 4 versions
M Combettes, C Kargar - Therapie, 2007 - edpsciences. org Abstract – Type 2 diabetes is an endocrine/metabolic disease characterized by
hyperglycemia. It is now well established that insulin resistance and pancreatic
β-cell dysfunction/failure are the two major components of the ... Cited by 10 - Related articles - All 3 versions
